
Dr. Adrian Minson discusses the latest lymphoma developments from EHA and ICML 2025, focusing on bispecific antibodies and key clinical trials.
In this episode of Blood Cancer Talks, we have Dr. Adrian Minson from the Peter MacCallum Cancer Centre to discuss the latest developments in lymphoma presented at the recent EHA and ICML meetings in June 2025. The episode focuses primarily on the emerging role of bispecific antibodies in various combinations and treatment settings for diffuse large B-cell lymphoma (DLBCL). Key Clinical Trials Discussed 1. POLARGO Trial - Polatuzumab + R-GemOx vs R-GemOx in R/R DLBCL 2. SUNMO Trial - Mosunetuzumab + Polatuzumab vs R-GemOx in R/R DLBCL 3. STARGLO Trial - Glofitamab + GemOx vs R-GemOx in R/R DLBCL (2-Year Update) 4. EPCORE NHL-5 & NHL-7 - Epcoritamab Combinations in Frontline DLBCL 5. EPCOR-RICE - Epcoritamab + R-ICE in Transplant-Eligible R/R DLBCL 6. LOTIS-7 Trial - Loncastuximab + Glofitamab in R/R DLBCL 7. Additional Studies Mentioned: R-Pola-Glo Frail Study DLBCL Classification
Hosts: Rajshekhar Chakraborty, Ashwin Kishtagari, Edward Cliff
Guest: Dr. Adrian Minson
Organizations: Peter MacCallum Cancer Centre
Products: bispecific antibodies, Polatuzumab, R-GemOx, Mosunetuzumab, Glofitamab, Epcoritamab, Loncastuximab
Books & works: diffuse large B-cell lymphoma (DLBCL)
Explore listener stats, chart rankings, contacts and more on the Blood Cancer Talks podcast page.